Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib phase 3 trial in biologic-naive active psoriatic arthritis
NL-OMON49695Phase 3Withdrawn
- Sponsor
- Gilead Sciences
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of filgotinib in psoriatic arthritis (PsA) (4 arms), sponsored by Gilead Sciences. Primary endpoints: ACR20 response at Week 12, Safety and 1 more. Planned start Oct 2020; status: withdrawn.
02
Drugs
filgotinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON49695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49695.